Name: ARBUTUS BIOPHARMA CORP (ABUS) Stock
Brand: ARBUTUS BIOPHARMA CORP
Rating: 7 (3 reviews)

ABUS Latest News, Press Relases and Analysis

All

Press Releases

26 days ago - By: Arbutus Biopharma Corporation

Arbutus Reports Third Quarter 2025 Financial Results and Provides Corporate Update

26 days ago - By: Arbutus Biopharma Corporation

Arbutus Reports Third Quarter 2025 Financial Results and Provides Corporate Update

2 months ago - By: Arbutus Biopharma Corporation

Arbutus Announces Four Abstracts Accepted for Presentation at AASLD - The Liver Meeting® 2025

3 months ago - By: Zacks Investment Research - Mentions: NVS

Is Novartis (NVS) Stock Outpacing Its Medical Peers This Year?

4 months ago - By: Zacks Investment Research - Mentions: AQST

Is Aquestive Therapeutics (AQST) Stock Outpacing Its Medical Peers This Year?

4 months ago - By: The Motley Fool

Arbutus (ABUS) Q2 Revenue Surges 529%

4 months ago - By: Zacks Investment Research - Mentions: CGON

Arbutus Biopharma (ABUS) Beats Q2 Earnings and Revenue Estimates

4 months ago - By: Arbutus Biopharma Corporation

Arbutus Reports Second Quarter 2025 Financial Results and Provides Corporate Update

4 months ago - By: Arbutus Biopharma Corporation

Arbutus Reports Second Quarter 2025 Financial Results and Provides Corporate Update

6 months ago - By: Arbutus Biopharma Corporation

Arbutus Reacquires Greater China Rights to Imdusiran and Announces Scientific Advisory Board with Late-Stage Clinical Focus

6 months ago - By: Arbutus Biopharma Corporation

Arbutus Reacquires Greater China Rights to Imdusiran and Announces Scientific Advisory Board with Late-Stage Clinical Focus

7 months ago - By: Zacks Investment Research - Mentions: MRSN

Arbutus Biopharma (ABUS) Reports Q1 Loss, Tops Revenue Estimates

7 months ago - By: Arbutus Biopharma Corporation

Arbutus Reports First Quarter 2025 Financial Results and Provides Corporate Update

7 months ago - By: Arbutus Biopharma Corporation

Arbutus Reports First Quarter 2025 Financial Results and Provides Corporate Update

7 months ago - By: Zacks Investment Research - Mentions: EDIT

Is Editas Medicine (EDIT) Stock Outpacing Its Medical Peers This Year?

7 months ago - By: Arbutus Biopharma Corporation

Arbutus Presents Clinical Trial Data from its Two HBV Assets, Imdusiran and AB-101, at the European Association for the Study of the Liver (EASL) Congress 2025

7 months ago - By: Arbutus Biopharma Corporation

Arbutus Presents Clinical Trial Data from its Two HBV Assets, Imdusiran and AB-101, at the European Association for the Study of the Liver (EASL) Congress 2025

8 months ago - By: Zacks Investment Research

Will Arbutus Biopharma (ABUS) Report Negative Q1 Earnings? What You Should Know

8 months ago - By: Arbutus Biopharma Corporation

Arbutus to Present Imdusiran and AB-101 Data at EASL Congress 2025

8 months ago - By: Arbutus Biopharma Corporation

Arbutus to Present Imdusiran and AB-101 Data at EASL Congress 2025

8 months ago - By: Zacks Investment Research

All You Need to Know About Arbutus (ABUS) Rating Upgrade to Buy

8 months ago - By: Zacks Investment Research - Mentions: AVAH

Is Arbutus Biopharma (ABUS) Outperforming Other Medical Stocks This Year?

9 months ago - By: Zacks Investment Research - Mentions: BMY

Arbutus Biopharma (ABUS) Reports Q4 Loss, Tops Revenue Estimates

9 months ago - By: Arbutus Biopharma Corporation

Arbutus Reports Fourth Quarter and Year End 2024 Financial Results and Provides Corporate Update

9 months ago - By: Arbutus Biopharma Corporation

Arbutus Reports Fourth Quarter and Year End 2024 Financial Results and Provides Corporate Update

9 months ago - By: Arbutus Biopharma Corporation - Mentions: ROIV

Genevant Sciences and Arbutus Biopharma Initiate International Patent Infringement Enforcement Actions Against Moderna

9 months ago - By: Arbutus Biopharma Corporation